Table 3 Ongoing clinical trials of combination treatment with other therapy
From: Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Clinical trial (NCT identifier) | Conditions | Treatment | Patients | n | Phase | States |
|---|---|---|---|---|---|---|
NCT04848116 | SCCHN | HuMax-IL8 + Nivolumab | SCCHN patients who will undergo surgery. | 24 | II | Recruiting |
NCT03689699 (MAGIC-8) | Prostate cancer | HuMax-IL8 + Nivolumab + ADT | Patients with prostatic adenocarcinoma | 60 | Ib/II | Active, not recruiting |
NCT02451982 | Pancreatic Cancer | HuMax-IL8 + Nivolumab | Patients with resectable pancreatic adenocarcinoma | 76 | II | Recruiting |
NCT04050462 | HCC | HuMax-IL8 + Nivolumab | Advanced HCC patients | 74 | II | Recruiting |
NCT03400332 | Advanced cancers | HuMax-IL8 + Nivolumab + Ipilimumab | Patients with advanced solid tumor | 372 | I/II | Recruiting |
NCT04123379 | NSCLC or HCC | HuMax-IL8 + Nivolumab | NSCLC or HCC patients | 50 | II | Recruiting |
NCT04572451 | Unresectable Solid Tumors | HuMax-IL8 + Nivolumab + SBRT | Patients with advanced / metastatic / unresectable solid tumors progressed on standard therapies | 50 | I | Recruiting |
NCT03161431 | Melanoma | SX-682 + Pembrolizumab | Patients with metastatic melanoma | 77 | I | Recruiting |
NCT04599140 (STOPTRAFFIC-1) | Colorectal cancer | SX-682 + Nivolumab | RAS-mutated, microsatellite stable, unresectable or metastatic Colorectal Cancer | 53 | I/II | Recruiting |
NCT04477343 | Pancreatic cancer | SX-682 + Nivolumab | Patients with metastatic pancreatic ductal adenocarcinoma | 20 | I | Recruiting |
